ETFS S&P Biotech rallied 10% from last week’s $52 low.
ETFS S&P Biotech is under Algo Engine buy conditions and is a current holding in our “ASX All ETF” model portfolio.
Watch for the short-term indicators to reverse higher as buying support begins to build near the $53 price level.
ETFS S&P Biotech is under Algo Engine buy conditions. Buying support has been building since the price traded at $58.
CURE ETF offers investors exposure to US biotechnology companies.
ETFS S&P Biotech is now under Algo Engine buy conditions.
CURE ETF offers investors exposure to US biotechnology companies. These are companies engaged in research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. Examples include the development of immunotherapy treatments and vaccines to treat human diseases.
CURE aims to provide investors with a return that, (before fees and expenses), tracks the performance of the S&P Biotechnology Select Industry Index. CURE uses a full-replication strategy to track the index, meaning that it holds all of the shares that make up the index. It is equal-weighted, meaning each holding makes up the same portion of the portfolio and therefore, contributes equally to the overall performance.